Proceedings of ICMMGH 2025 Symposium: Computational Modelling in Biology and Medicine
DOI: 10.54254/2753-8818/91/2025.GU21567

Application of Genomics Technology in Alzheimer's Disease

Yuzhu Li[1,a,*]

[1]*Aix-Marseille School, Wuhan University of Technology, Wuhan, Hubei, 430070, China*
a. 3050761478@qq.com
**corresponding author*

Abstract: Alzheimer's disease (AD) is a complicated neurodegenerative disorder. As the symptoms worsen, patients will experience language disorders, memory loss, and other symptoms. Its pathogenesis has not yet been fully elucidated. however, the development of genomics technology has offered novel perspectives and tools for the study of AD. This paper summarizes the application of genomics technology in AD, including the identification of genetic risk genes, the elucidation of disease mechanisms, the recognition of disease subtypes, and research progress in precision medicine and drug development. The research results show that through Genome-Wide Association Studies (GWAS), single-cell sequencing, and epigenetics, researchers can offer deeper insights into the genetic basis and molecular mechanisms of AD, providing new possibilities for the early diagnosis and personalized treatment of the disease. Although these technologies have helped people gain a deeper understanding of AD, there remain more complex mechanisms that need to be explored and solved in the future.

Keywords: Alzheimer's disease, Genomics, Genetic risk genes, Disease mechanisms, Precision medicine

1. Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder that begins insidiously and progresses progressively, mainly affecting the elderly and bringing a heavy burden to patients and their families. As the global population ages increasingly, the incidence of AD is rising year by year. It is estimated that by 2050, the number of AD patients worldwide will exceed 130 million [1]. Despite the significant investments of human and material resources in AD by the medical community, the exact pathogenesis of AD has not yet been fully clarified, and there is still no effective cure. Current treatment methods mainly focus on alleviating symptoms and slowing the progression of the disease, such as the use of acetylcholinesterase inhibitors and NMDA receptor antagonists, but the efficacy of these drugs is limited and they have certain side effects.

The rapid advancements of genomics technology have brought new hope for the study of AD. Genomics is a discipline that studies the function, structure, and evolution of the genome. Through high-throughput sequencing technology, scientists can comprehensively and deeply analyze the sequence information of the human genome and reveal the complex relationships between genes and diseases.

This paper reviews the use of genomics technology in AD, with an emphasis on identifying identification of genetic risk genes, clarifying disease mechanisms, clarifying disease subtypes, and

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/91/2025.GU21567

advancing precision medicine and medication development. By systematically summarizing the current research results, it aims to provide a scientific basis and theoretical support for the future prevention and treatment of AD, promote the further development and application of genomics technology in this field, and bring renewed hope and blessings to patients.

2. Theoretical Introduction

Current research on Alzheimer's disease mainly focuses on genomics technology, biomarker research, drug development, and clinical trials. Within this framework, genomics technology mainly includes genome-wide association studies, single-cell sequencing, and epigenetics research, which will be discussed in detail below.

2.1. Genome-Wide Association Studies

Powerful tools, Genome-Wide Association Studies (GWAS) can identify genetic variations connected with complex diseases or traits. GWAS scans a large number of Single Nucleotide Polymorphisms (SNPs) across the entire genome to identify gene regions associated with diseases or traits [2]. This method can detect the association between genetic variations and phenotypes across the entire genome, revealing the collective impact of these minor-effect genes on complex diseases [3]. In addition, GWAS can discover new disease-causing genes and biological pathways, and has been widely used in the genetic research of complex diseases [4].

In GWAS, researchers first collect DNA samples from a large number of cases (individuals with the target disease) and controls (healthy individuals). High-throughput genotyping technology is then employed to genotype these samples for SNPs. GWAS tests hundreds of thousands to millions of SNPs, which cover the entire genome. By comparing the allele frequency differences at each SNP locus between the case and control groups, researchers can identify SNPs that are significantly associated with disease risk. These association signals may point to specific genes or gene regions, providing clues for further functional studies [5].

2.2. Single-Cell Sequencing Technology

Single-cell sequencing technology is a revolutionary genomics tool that can comprehensively analyze gene expression, genomic variations, and epigenetic modifications at the single-cell level. The core of single-cell sequencing technology is to separate single cells and perform high-throughput sequencing. First, single cells are isolated from tissue samples using microfluidic technology, flow cytometry, or laser capture microdissection. Then, RNA or DNA from each cell is extracted and amplified, followed by high-throughput sequencing. The sequencing data is analyzed using bioinformatics, overcoming the limitations of traditional sequencing methods in processing cell populations. It can display the gene expression profile, genomic variations, and epigenetic modification status of each cell, revealing the cellular heterogeneity and dynamic changes in the development of diseases, and providing a new perspective for understanding complex biological systems and disease mechanisms [6].

2.3. Epigenetics Research

Epigenetics research technology is an important means to explore gene expression regulation and genome function. It studies function without altering the DNA sequence and heritable changes in gene expression. These changes mainly occur through mechanisms like DNA methylation, histone modification, and non-coding RNA, playing a vital role in regulating of gene transcription, translation, and function. In recent years, advancements in technologies such as whole-genome

DOI: 10.54254/2753-8818/91/2025.GU21567

bisulfite sequencing (WGBS) and RNA sequencing (RNA-Seq) have enabled researchers to comprehensively and systematically analyze the epigenetic modification status of the genome, elucidate the role of epigenetic modifications in disease development, and provide new targets and strategies for disease diagnosis, treatment, and prevention [7].

DNA methylation is one of the most common epigenetic modifications, which mainly occurs on CpG islands, that is, the dinucleotide sequence of cytosine and guanine. DNA methylation is usually associated with gene silencing. The addition of a methyl group to DNA alters the chromatin structure, thereby inhibiting gene transcription.

Histone modifications involve methylation, phosphorylation, acetylation, and other forms. These modifications can change the structure and function of chromatin, thereby affecting gene transcription activity. Histone acetylation is usually associated with gene activation, while histone methylation can activate or inhibit gene expression, depending on the site and type of modification.

Non-coding RNA (ncRNA), a class of RNA molecules, does not encode proteins, including microRNA (miRNA) and long non-coding RNA (lncRNA). These non-coding RNAs regulate gene expression and function by binding to mRNA. miRNA binds to the 3' untranslated region (3'UTR) of mRNA, leading to mRNA degradation or inhibition of its translation, thereby negatively regulating gene expression [8]. lncRNA regulates gene expression and function through various mechanisms, such as forming chromatin loops, recruiting transcription factors, and regulating gene splicing.

In recent years, the development of genomics technology has greatly promoted the field of biomedical research, bringing blessings to the diagnosis, treatment, and prevention of complex diseases.

3. Application of Genomics Technology in Alzheimer's Disease

The following sections discuss the integration and coordinated development of these technologies in the study of Alzheimer's disease.

3.1. Application of Genome-Wide Association Studies

Genome-wide association studies (GWAS) have become a key tool for revealing the genetic basis of Alzheimer's disease (AD) in its detection.

In the study of AD, GWAS has successfully identified several genetic loci significantly associated with disease risk. Lambert et al. conducted a pioneering study that analyzed the genomes of more than one million AD patients and healthy controls, confirming the strong association between the known APOEε4 allele and AD [9]. APOEε4 is the strongest known genetic risk factor for AD, and its presence significantly increases an individual's risk of developing AD. In addition, the study also discovered 11 new AD risk loci, such as Clusterin (CLU), the CR1, and phosphatidylinositol-binding clathrin assembly protein (PICALM) genes. Variations in the CR1 gene are linked with abnormal immune system function, suggesting that dysfunctional immune responses may lead to neuroinflammation, resulting in neuronal damage and death, which plays a critical role in the development of AD. The variation of CLU gene is related to lipid metabolism, and the disorder of lipid metabolism may affect the health and function of neurons. Furthermore, variations in the PICALM gene are associated with neurotransmitter transmission, where abnormalities in this process may impair communication between neurons, leading to cognitive decline.

In terms of clinical application, Jansen et al. used GWAS data from multiple genetic risk loci to construct a polygenic risk score (PRS) for AD. They found that individuals at high risk showed more significant differences in cognitive decline and pathological changes [10]. This integrated

DOI: 10.54254/2753-8818/91/2025.GU21567

approach, combining GWAS and PRS, allows for the cumulative effects of these loci to be assessed, enabling more accurate identification of high-risk individuals. Consequently, this method facilitates early screening, intervention, and treatment of AD.

3.2. Application of Single-Cell Sequencing Technology

Single-cell sequencing technology has become an important tool for revealing disease cell heterogeneity and molecular mechanisms in the detection of Alzheimer's disease (AD). By analyzing the gene expression profiles of individual cells, researchers can more accurately understand the role of different types of neurons in AD and reveal the dynamic changes in disease progression.

Mathys et al. used single-cell sequencing technology to analyze the cellular heterogeneity in the brains of AD patients and found that the immune/glial cell-related module is strongly associated with the pathogenesis of AD [11]. Researchers performed single-cell RNA sequencing on brain samples from AD patients and healthy controls and found that glial cells showed significant inflammatory responses in the early stages of AD, with their gene expression profiles showing an increase in markers related to immune activation. These inflammatory responses may further exacerbate neuronal damage and death, indicating that the activation state of glial cells in AD is closely related to neuronal degeneration.

In another study, researchers further used single-cell sequencing technology to analyze the microglia in the brains of AD patients and found that these cells exhibited different gene expression profiles at different stages of disease progression [12]. Specifically, in the early stages of AD, microglia mainly showed an increase in gene expression related to inflammatory responses, which may be related to the clearance of extracellular amyloid deposits and the regulation of neuroinflammation. However, as the disease progresses, the gene expression profile of these cells gradually shifts to an increase in markers related to apoptosis and tissue repair. This dynamic change indicates that microglia may play various roles at different stages of AD. They may combat pathological changes through inflammatory responses in the early stage, while, they may be more involved in apoptosis and tissue repair processes in the late stage.

These findings provide new ideas for the development of therapeutic strategies targeting microglia, suggesting that future treatments may need to be personalized according to different stages of the disease.

3.3. Application of Epigenetics Research

Epigenetics research has become an important means for revealing the pathogenesis of Alzheimer's disease (AD) and developing early diagnostic markers in the detection of AD. Epigenetic modifications can influence gene expression without changing the DNA sequence, and these modifications play a key role in the development of AD.

In AD research, DNA methylation analysis has revealed several methylation sites linked with the disease. Hannon et al. found that the DNA methylation levels of the ANK1, BIN1, and RHBDF2 genes in the brains of AD patients were significantly altered, and these methylation states were closely related to cognitive decline [13]. In the brains of AD patients, the DNA methylation level of the ANK1 gene was significantly increased, which may inhibit the expression of the ANK1 gene. The protein encoded by the ANK1 gene plays an important role in the stability of the cytoskeleton and the survival of neurons, and its downregulation may exacerbate neuronal damage and death. The methylation level of the BIN1 gene also changed significantly, and the BIN1 gene is related to neuronal endocytosis and synaptic function, the change of its methylation state may affect the normal function of neurons. The methylation level of the RHBDF2 gene also showed significant

DOI: 10.54254/2753-8818/91/2025.GU21567

changes in AD patients, and the gene is related to intercellular signaling and immune response, the change of its methylation state may affect the progression of neuroinflammation.

In addition, histone modifications play a crucial role in the pathogenesis of AD. Heintzman et al. studied the distribution of histone H3K4 trimethylation (H3K4me3) and H3K27 trimethylation (H3K27me3) in the brains of AD patients and found that they were closely related to gene expression regulation [14]. H3K4me3 is usually related to gene activation, while H3K27me3 is associated with gene silencing. The study found that the level of H3K4me3 in the promoter regions of some genes in the brains of AD patients was significantly reduced, while the level of H3K27me3 was significantly increased. This change indicates that the expression of these genes may be inhibited, thereby affecting the normal function and survival of neurons.

In the field of non-coding RNA, the regulatory roles of miRNA and lncRNA have also attracted widespread attention. Bartel's research shows that miRNA regulates gene expression by binding to the 3' untranslated region (3'UTR) of mRNA, affecting the pathological process of AD [15]. The expression level of miRNA-125b in the brains of AD patients is significantly increased, and it may inhibit the expression of the BACE1 gene, thereby affecting the production of β-amyloid [16]. In addition, lncRNA also regulates gene expression through various mechanisms, such as forming chromatin loops and recruiting transcription factors, participating in the pathogenesis of AD [17].

4. Challenges and Prospects

Genomics technology has made significant progress in the study of Alzheimer's disease, providing new tools and methods for the early diagnosis, precision medicine, and drug development of the disease. Through genome-wide association studies, single-cell sequencing, and epigenetics, researchers can gain a deeper appreciation of the genetic basis and molecular mechanisms of AD.

However, genomics technology also faces some challenges in AD research, such as the difficulties of data integration and analysis, as well as translating research findings into clinical applications. The data generated by genomics technology is huge and involves information at multiple levels. At present, although there are some bioinformatics tools and methods for data integration, the accuracy and reliability of these tools still require further enhancement. In addition, translating genomics findings into clinical applications is also a complex process that involves multiple links, including the development of biomarkers, validation of drug targets, and the formulation of personalized treatment plans. Ensuring the effectiveness and safety of these tools and methods in different populations, while also addressing ethical and legal issues, are critical issues that need to be solved. These challenges indicate that although genomics technology has provided a new perspective for AD research, overcoming technical and biological barriers is essential for its widespread clinical application.

With the continuous progress of technology, the integration of genomics technology with other omics technologies may become an important means to reveal the complex pathological mechanisms of AD. By integrating genomics, transcriptomics, proteomics, and metabolomics data, researchers can gain a more comprehensive understanding of the molecular basis of AD. In addition, the improvement of gene editing technologies, such as, CRISPR-Cas9 will provide new tools for functional validation and the development of therapeutic strategies. The combination of these technologies not only has the potential to improve the accuracy and timeliness of diagnosis but also lays the groundwork for developing more effective treatments.

Future research will focus on addressing current technical challenges and promoting the application of genomics technology in the prevention and treatment of AD, in order to provide patients greater hope and blessings.

DOI: 10.54254/2753-8818/91/2025.GU21567

5. Conclusion

Genomics technology has made significant progress in the study of Alzheimer's disease. Through GWAS and other methods, researchers have identified several genetic risk genes associated with AD, providing possible targets for early prediction and prevention of the disease. The application of single-cell sequencing technology allows researchers to gain a more precise understanding of the role of different neurons in AD at the single-cell level. Epigenetics research has revealed the important role of DNA methylation and other modifications in AD, providing new ideas for disease treatment. In addition, genomics technology has also promoted the recognition of AD disease subtypes and the development of precision medicine.

However, this article lacks experimental data support and mainly relies on published research findings. This limitation may affect the depth and breadth of the research results and cannot directly verify the effectiveness and reliability of these technologies in practical applications. In addition, this article discusses the application of various genomics technologies in AD research, but these technologies each have their own limitations, which may affect the comprehensiveness of the research results.

Future research can further integrate genomics, transcriptomics, proteomics, and metabolomics data to construct a more comprehensive disease model, providing a broader perspective for understanding the complex pathological mechanisms of AD. Looking ahead, with the continuous development and application of genomics technology, greater breakthroughs are expected in the prevention and treatment of AD. Through further genomics research, more genetic risk genes and disease-related pathways can be discovered, providing a more accurate basis for early prediction and personalized treatment of the disease.

References

[1] *Alzheimer's Disease International. (2019). World Alzheimer Report 2019: Attitudes to Dementia. London: Alzheimer's Disease International.*

[2] *Pan, D., Li, Z., Zhang, W., & Li, Q. (2014). A Review of Genome-Wide Association Studies [J]. Applied Probability and Statistics, (1): 84-103.*

[3] *Manolio, T. A., Collins, F. S., Cox, N. J., et al. (2009). Finding the missing heritability of complex diseases. Nature. 461(7265):747-753. doi:10.1038/nature08494*

[4] *Hindorff, L. A., Sethupathy, P., Junkins, H. A., et al. (2009). Potential etiologic and functional implications of genome-wide association studies for human diseases and traits. Proceedings of the National Academy of Sciences of the United States of America, 106(23): 9362-9367.*

[5] *Macosko, E. Z., Basu, A., Satija, R., et al. (2015). Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell, 161(5): 1202-1214.*

[6] *Han, X., Zhou, Z., Li, F., et al. (2020). Construction of a human cell landscape at single-cell level. Nature, 581(7808), 304-309.*

[7] *Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., et al. (2015). Integrative analysis of 111 reference human epigenomes. Nature, 518(7539), 317-330.*

[8] *Bartel, D. P. (2009). MicroRNAs: Target recognition and regulatory functions. Cell, 136(2), 215-233.*

[9] *Lambert, J. C., Ibrahim-Verbaas, C. A., Harold, D., et al. (2013). Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 45(12), 1452-1458.*

[10] *Jansen, I. E., Savage, J. E., Watanabe, K., et al. (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nature Genetics, 51(3), 404-413.*

[11] *Mathys, H., Davila-Velderrain, J., Peng, Z., et al. (2019). Single-cell transcriptomic analysis of Alzheimer's disease. Nature, 570(7761), 332-337.*

[12] *Jin, S., Papadopoulos, Z., Wang, Y., et al. (2021). Single-nucleus RNA-seq of matched cerebrospinal fluid and brain reveals cellular alterations in Alzheimer's disease. Nature Communications, 12(1), 1-14.*

[13] *Hannon, E., Spiers, H., Viana, J., et al. (2019). Methylation of the ANK1 gene is associated with Alzheimer's disease neuropathology and downregulates ANK1 gene expression. Molecular Psychiatry, 24(10), 1493-1501.*

[14] *Heintzman, N. D., Hon, G. C., Hawkins, R. D., et al. (2009). Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature, 459(7243), 108-112.*

DOI: 10.54254/2753-8818/91/2025.GU21567

[15] Bartel, D. P. (2009). MicroRNAs: Target recognition and regulatory functions. Cell, 136(2), 215-233.

[16] Wang, K., Long, B., Zhou, L., et al. (2013). MicroRNA-21 promotes cell proliferation and inhibits apoptosis in human osteosarcoma cells by targeting PTEN. Biochemical and Biophysical Research Communications, 439(3), 423-428.

[17] Rinn, J. L., & Chang, H. Y. (2012). Genome regulation by long noncoding RNAs. Annual Review of Biochemistry, 81, 145-166.